Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma

被引:86
作者
Tedeschi, R [1 ]
Enbom, M
Bidoli, E
Linde, A
De Paoli, P
Dillner, J
机构
[1] IRCCS, Ctr Riferimento Oncol, Microbiol Immunol & Virol Dept, Aviano, Italy
[2] IRCCS, Ctr Riferimento Oncol, Epidemiol Unit, Aviano, Italy
[3] Karolinska Inst, Microbiol & Tumor Biol Ctr, S-10521 Stockholm, Sweden
[4] Karolinska Inst, Swedish Inst Infect Dis Control, S-10521 Stockholm, Sweden
[5] MAS Univ Hosp, Dept Med Microbiol, Malmo, Sweden
关键词
D O I
10.1128/JCM.39.12.4269-4273.2001
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Viral load is an important marker of activity of viral diseases for a number of viruses. We wished to evaluate whether the viral load of human herpesvirus 8 (HHV-8) in peripheral blood was a consistent feature of Kaposi's sarcoma (KS) patients and whether the viral load correlated with human immunodeficiency virus (HIV) RNA levels, CD4 counts, and/or the HHV-8 seroreactivity. Fifty-four consecutive plasma samples from 14 patients with KS were evaluated for HHV-8 viral load by quantitative real-time PCR. Samples were analyzed at the start of highly active antiretroviral therapy (HAART) and at different intervals during treatments. The median HHV-8 DNA load before HAART treatment was 8,998 (ranging from 170 to 40,100) copies/ml and 12,270 (ranging from 40 to 142,575) copies/ml during HAART. There were both increasing and decreasing trends. There was an association between HHV-8 DNA and HIV RNA viral loads (odds ratio [OR] = 5.40; 95% confidence interval [95% CI], 1.54 to 18.98) and between HHV-8 viral load and CD4 cell counts (OR = 7.24; 95% CI, 1.30 to 40.35). High HHV-8 viral load was also correlated with the titers of antibodies to the lytic HHV-8 antigen detected with immunofluorescence (P < 0.01), but not with antibodies to the latent HHV-8 antigen. In conclusion, we found that HHV-8 viremia in KS is associated with HIV viral load, CD4 cell counts, and lytic HHV-8 serological reactivity. HHV-8 viral load monitored by real time PCR might be useful for determination HHV-8 viral load during the follow-up of KS patients.
引用
收藏
页码:4269 / 4273
页数:5
相关论文
共 54 条
[31]   Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma [J].
Lebbé, C ;
Blum, L ;
Pellet, C ;
Blanchard, G ;
Vérola, O ;
Morel, P ;
Danne, O ;
Calvo, F .
AIDS, 1998, 12 (07) :F45-F49
[32]   Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients [J].
Lennette, ET ;
Blackbourn, DJ ;
Levy, JA .
LANCET, 1996, 348 (9031) :858-861
[33]   Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease [J].
Li, TS ;
Tubiana, R ;
Katlama, C ;
Calvez, V ;
Ait Mohand, H ;
Autran, B .
LANCET, 1998, 351 (9117) :1682-1686
[34]  
LO YM, CANC RES, V59, P5452
[35]  
Martinelli C, 1998, AIDS, V12, P1717
[36]   Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: Association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels [J].
Min, J ;
Katzenstein, DA .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (01) :51-55
[37]   Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma [J].
Moore, PS ;
Kingsley, LA ;
Holmberg, SD ;
Spira, T ;
Gupta, P ;
Hoover, DR ;
Parry, JP ;
Conley, LJ ;
Jaffe, HW ;
Chang, Y .
AIDS, 1996, 10 (02) :175-180
[38]   Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin [J].
Núñez, M ;
Machuca, A ;
Soriano, V ;
Podzamczer, D ;
González-Lahoz, J .
AIDS, 2000, 14 (08) :913-919
[39]   Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy [J].
Orenstein, JM ;
Alkan, S ;
Blauvelt, A ;
Jeang, KT ;
Weinstein, MD ;
Ganem, D ;
Herndier, B .
AIDS, 1997, 11 (05) :F35-F45
[40]   A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients [J].
Pialoux, G ;
Raffi, F ;
Brun-Vezinet, F ;
Meiffrédy, V ;
Flandre, P ;
Gastaut, JA ;
Dellamonica, P ;
Yeni, P ;
Delfraissy, JF ;
Aboulker, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) :1269-1276